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MECHANISTIC MODELS FIT TO ED001 DATA ON >40,000 TROUT EXPOSED
TO DIBENZO[A,L]PYRENE INDICATE MUTATIONS DO NOT DRIVE
INCREASED TUMOR RISK
Kenneth T. Bogen   Exponent Inc., Health Sciences
  ED001-study data on increased liver and stomach tumor risks in >40,000 trout fed diben-
zo[a,l]pyrene (DBP), one of the most potently mutagenic chemical carcinogens known,
provide the greatest low-dose dose-response resolution of any experimentally induced
tumor data set to date. Although multistage somatic mutation/clonal-expansion cancer
theory predicts that genotoxic carcinogens increase tumor risk in linear no-threshold pro-
portion to dose at low doses, ED001 tumor data curiously exhibit substantial low-dose non-
linearity. To explore the role that nongenotoxic mechanisms may have played to yield such
nonlinearity, the liver and stomach tumor data sets were each fit by two models that each
assume a genotoxic and a nongenotoxic pathway to increased tumor risk: the stochastic 2-
stage (MVK) cancer model, and a model implementing the more recent dysregulated adap-
tive hyperplasia (DAH) theory of tumorigenesis. MVK and DAH fits to the data sets were
each excellent, but unexpectedly each MVK fit implies that DBP acts to increase tumor risk
by entirely non-mutagenic mechanisms. Given that DBP is such a potent mutagen, the
MVK-model fits obtained appear to be biologically implausible, whereas the DAH-model
fits reflect that model’s assumption that chemical-induced tumorigenesis typically is driven
by elevated repair-cell populations rather than mutations per se.
Key terms: bioassay, cancer, low-dose linearity, biologically based models, tumorigenesis, mutagen
INTRODUCTION
A default linear no-threshold (LNT) approach to extrapolate
increased cancer risks from environmental chemical carcinogen expo-
sures has been applied by the U.S. Environmental Protection Agency
(EPA) over the last 45 years, particularly (more recently) for carcinogens
known or assumed to have a genotoxic mode of action (MOA). The LNT
approach has always been based explicitly on the hypothesis that critical
DNA mutations are key, rate-limiting events that can drive tumorigenesis,
in accordance with the multistage somatic mutation theory of cancer
(U.S. EPA 1976, 1986, 2005, 2007; Anderson et al. 1983). A stochastic two-
stage/clonal-expansion version of this model was proposed originally by
Armitage and Doll (1957), shortly after Watson and Crick deciphered the
structure of DNA and basic elements of genetic machinery were being
elucidated. This model posits that a rare, critical somatic mutation can
transform a normal “stem” cell (i.e., any cell not terminally differentiat-
Address correspondence to: K.T. Bogen, DrPH, DABT, Exponent Inc., Health Sciences,
475 14th Street, Ste 400, Oakland, CA USA 94612, kbogen@exponent.com, tel 510-268-5048, fax
510-268-5099.
1
Bogen: Models Fit to ED001 Tumor Data
Published by ScholarWorks@UMass Amherst, 2014
ed that is capable of dividing) into a premalignant cell that tends to pro-
liferate over time, and another such mutation can transform any prema-
lignant cell into a tumor cell. This two-stage/clonal-expansion model was
later refined by Moolgavkar, Venzon, Knudson (MVK) and others
(Moolgavkar and Venzon 1979; Moolgavkar and Knudson 1981;
Moolgavkar 1983, 1988; Moolgavkar et al. 1988, 1989; Moolgavkar and
Luebeck 1990; Leubeck et al. 1999), who obtained the exact algebraic
solution that arises if this model is represented as a doubly stochastic
Poisson process with parameters that are piecewise-homogeneous over
any k time intervals.
According to the somatic-mutation/clonal-expansion theory, agents
can increase tumor risk not only by causing mutations, but also (or sole-
ly) by increasing the number of premalignant cells that are at risk for
undergoing malignant transformation by a dose-induced (or sponta-
neous background) mutation. It has thus become recognized that LNT
cancer risk extrapolation is likely to be conservative even for genotoxic
chemical carcinogens, to the extent that they happen also to increase
tumor risk by inducing net premalignant-cell proliferation and/or geno-
toxic endpoints at tumorigenic doses, in the case that each such endpoint
also happens to have a substantially nonlinear or threshold dose-response
(NRC 1994; Bolt et al. 2004; O’Brien et al. 2006). However, if tumorigen-
esis requires one or more critical somatic mutations that can be induced
in linear proportion to dose (as assumed by the somatic mutation theory
of cancer and implementations of it, such as the MVK mode), then by def-
inition a linear, mutagenic-potency coefficient in dose must dominate at
very low doses. Consequently, for potently mutagenic chemical carcino-
gens, an LNT dose-response relationship for increased cancer risk is wide-
ly assumed to be both scientifically plausible and reasonably likely.
The ED001 (“mega-trout”) ultra-low-dose bioassay generated detailed
data on elevated liver and stomach tumor incidence observed in a total of
>40,000 trout, eight groups of which were exposed to concentrations
ranging from 0 to 225 ppm of dibenzo[a,l]pyrene (DBP) in food for four
weeks, followed by normal diet for nine months (Bailey et al. 2009;
Williams et al. 2003; 2009). This was and remains the largest single cancer
bioassay study ever done, which generated the highest resolution set of
tumor dose-response data, of any bioassay ever conducted using any type
of experimental animal. The ED001 study design took advantage of the
fact that trout are a flexible and established model of animal carcinogen-
esis that can be applied efficiently, using relatively large numbers of indi-
vidual animals (Dashwood et al. 1999; Reddy et al. 1999a b; Williams et al.
2003, 2009; Benninghoff et al. 2012).
The “model genotoxic” chemical and “tumor initiator” used in the
ED001 study, DBP, is one of the most potently mutagenic chemical car-
cinogens known (Higginbotham et al. 1993; Busby et al. 1995; Prahalad et
Models Fit to ED001 Tumor Data
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al. 1997; Chakravarti et al. 1995; 2000; Williams et al. 2003; Mahadevan et
al. 2005; Plísková et al. 2005; Mourón et al. 2006; DeMarini et al. 2011;
Guttenplan et al. 2012). DBP requires metabolic activation by species-spe-
cific cytochrome P450 enzymes to generate DNA adducts, mutations,
chromosome damage, and tumors (Buters et al. 2002; Schober et al. 2006;
Kushman et al. 2007; Lagerqvist et al. 2008; Topinka et al. 2008; Meschini
et al. 2010). From additional analyses done on stomach-tissue samples in
the ED001 study, Bailey et al. (2009) concluded that there was “clear evi-
dence from stomach tumors that DBP-driven mutations in the Ki-ras
oncogene were present even at low dose.” In Big Blue mouse cells
exposed to diol-epoxide metabolites of DBP for 30 min in vitro, both DBP-
DNA adducts and cII mutations increased in approximate proportion to
exposure concentration (Yoon et al. 2004). Such approximate propor-
tionality was also observed between exposure-induced lacZmutations and
bulky DNA adducts measured in different tissues of groups of 25-week-old
male transgenic MutaTMMouse mice dosed daily with the DBP-related
polycyclic aromatic hydrocarbon, benzo(a)pyrene (BaP) (Lemieux et al.
2011). BaP-DNA-adduct levels measured in those mice were highest in
glandular stomach and liver, which Lemieux et al. ( 2011) pointed out
were sites of first BaP contact and of primary BaP metabolism, respec-
tively—factors also likely to have applied to the DBP that was adminis-
tered in food to ED001-study trout that exhibited exposure-induced
tumors in the same two target tissues.
Because DBP is one of the most potently mutagenic carcinogens
known, it is surprising that ED001 dose-response data on liver and stomach
tumors in DBP-exposed fish were reported to exhibit substantial nonlin-
earity at low doses (Williams et al. 2003; Bailey et al. 2009). Bailey et al.
(2009) concluded that, among nine statistical/regression-type risk mod-
els explored, three models (linear probit, quadratic logit, and Ryzin-Rai)
that each fit the ED001 liver tumor data well predicted increased risks that
fell increasingly below default benchmark-dose-type regulatory extrapo-
lation assumptions with decreasing DBP dose, that low-dose tumor
response was not predictable from hepatic DBP-DNA adduct biomarkers,
and thus that ED001 data provided the first experimental demonstration
that EPA default LNT assumptions for genotoxic carcinogens are inher-
ently conservative. Specifically, observed log liver-tumor likelihood and
corresponding log DBP concentration were found to exhibit a substan-
tially nonlinear (i.e., >1) slope of ~2.3 that was significantly greater 
(p = 0.0007) than that of ~1.3 exhibited between the log of the number
of bulky DBP-DNA adducts measured in liver and log DBP concentration
(Bailey et al. 2009). However, goodness-of-fit values for these relationships
were not reported, mechanistic cancer models were not applied, and spe-
cific mechanistic hypotheses consistent with ED001 study data were not dis-
cussed.
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It is possible that, due to DBP-induced cytotoxicity, DBP may act with
a dual MOA to increase tumor risk via a combination of mutagenic and
nongenotoxic-promotion mechanisms. For example, DBP can potently
transform cells in vitro even in the absence of detected DNA adducts
(Nesnow et al. 1997; 2000). DBP can also reduce clonogenic survival by
triggering cytoxicity and apoptosis, as well as trigger cell proliferation, par-
ticularly at DBP or DBP-metabolite concentrations exceeding 10 to 100
ppb in several cell types studied in vitro (Busby et al. 1995; Nesnow et al.
1997; Yoon et al. 2004; Plísková et al. 2005; Schober et al. 2006; Kushman et
al. 2007; Topinka et al. 2008) and in livers of trout exposed to DBP in vivo
5 days/week for four weeks (Zipperman 1999). Tumor-response patterns
observed in the ED001 study may therefore be consistent with predictions
made by a biologically based, mechanistic cancer-risk model that accounts
explicitly for dual-MOA pathways of tumorigenesis.
The specific aim of the present study was to examine the dual-MOA
hypothesis for DBP quantitatively, using the biologically based, mechanis-
tic MVK cancer model that explicitly incorporates separate mutagenic
and premalignant-cell-proliferation pathways to increased levels of pre-
dicted tumor risk. Specifically, the MVK model was fit to ED001 dose-
response data on liver and stomach tumor incidence in DBP-exposed
trout, and relative impacts associated with best estimates of MVK param-
eters governing mutation and those governing premalignant-cell prolif-
eration were calculated for each tumor endpoint.
For comparison, the ED001 data were also fit to a biologically based,
mechanistic cancer risk model that differs fundamentally from the MVK
model, by predicting that tumorigenic exposures, including those involv-
ing potent mutagens, typically act to increase tumor risk predominantly
or virtually exclusively by increasing not mutation rates, but rather the
number of cells engaged in adaptive hyperplasia (AH) in response to
exposure-induced cytotoxic stress. Specifically, the “dysregulated AH”
(DAH) model (Figure 1) assumes that incipient tumors arise when a stem
cell that has been recruited into a (normally rare) somatically propagat-
ed AH state or program (such as that normally invoked to regenerate or
repair injured or infected tissue), also contains a rare DNA mutation that
blocks the normal ability of an AH-state cell to terminate AH (Bogen
2013). The DAH model is thus a one-step, state-dependent model of
tumorigenesis. Because tissue repair and regeneration normally occur
only sporadically throughout life, the DAH model implies that the pool
of cells that most readily generate tumors is typically relatively small, but
subject to periodic expansion and contraction (Bogen 2013). In contrast,
the MVK model assumes that all stem cells in each tissue are susceptible
to tumorigenic mutations.
Details concerning the ED001 data that were fit, specific mathematical
model representations, and fitting procedures are described in Methods.
Models Fit to ED001 Tumor Data
389
4
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 3, Art. 5
https://scholarworks.umass.edu/dose_response/vol12/iss3/5
Results obtained are then presented, followed by a discussion that inter-
prets these results and their implications for future related research.
METHODS
Bioassay Data
To explore dose-response down to a targeted 10 excess liver tumors
per 10,000 animals (ED001), a total of 40,800 Shasta strain rainbow trout
fry (Oncorhynchus mykiss), initially at ~1.5 g body weight, were administered
Oregon Test Diet (OTD), or OTD mixed with 0.450, 1.27, 3.57, 10.1, 28.4,
80.0, or 225 ppm DBP for 4 weeks, then were fed control diet for 9 months
(Bailey et al. 2009). The incidence of stomach and liver tumors was record-
ed during exposure, the 9-month post-exposure period, or sacrifice at ~12
±0.5 months. Based on reported body weight, the exposure period was
modeled to occur during month three of the 12-month exposure period
(FAO 2011). Separate enumeration of benign vs. malignant tumors was
not provided (Bailey et al. 2009, Tables 1 and S1), but data from similar
studies indicate that potent genotoxic polycyclic aromatic hydrocarbons
such as aflatoxin B1 and DBP can elicit predominantly malignant tumors
K. T. Bogen
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FIGURE 1. Stress-dependent tumorigenic pathways posited by the “dysregulated adaptive hyperpla-
sia” (DAH) theory (Bogen 2013). Two types of stress (downward green “Sublethal stress” and “Cell
killing” arrows) transform normal stem cells (N) to protective (P) or regenerative (R) phenotypes,
respectively, epigenetically maintained by corresponding microRNA-expression profiles. A critical
somatic mutation mB or mM (horizontal black dashed arrows) can transform an N-cell to one that is
potentially prebenign (NB) or potentially premalignant (NM), respectively, or likewise can transform
P- or R-cells to corresponding prebenign (PB) or premalignant (PM) proliferative cells. The critical
mutation prevents normal transduction (blue “Resolution” arrows) of a tissue-specific signal required
to resolve stress-induced P- or R-type adaptive hyperplasia. Conditional on surviving immune sur-
veillance, net proliferation yields slow or more rapid clonal expansion of PB or PM cells, respectively.
Surviving PB clones are benign tumors. Similar to mammalian cells in tissue culture, PM clones
inevitably undergo telomere crisis, after which each surviving cell is an incipient malignant tumor
cell. 
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(Reddy et al. 1999a; Williams 2012). Data from each set of four separate
groups of trout that were administered the same dose were combined into
one group per dose, and corresponding dose-specific chi-square tests were
performed to test for consistency with binomial sampling error of tumor
counts within each dose group. Only liver tumors in the 28.4-ppm dose
group failed this test (p < 10–6), and a corresponding extended Fisher
exact test (p < 10–5) (Baglivo et al. 1988), and for this dose group, the stan-
dard error was taken to be the empirical standard deviation (0.0759) of
the four corresponding observed incidence rates.
Dose-Response Models
The MVK (two-stage doubly stochastic clonal-expansion) model of
cancer risk posits that a critical oncogene mutation occurring at rate m1
causes a transition from a normal stem cell (N) to a stage-one or prema-
lignant cell (P), and another mutation occurring at rate m2 causes a tran-
sition of a P cell to an incipient cancer cell (M). N- and P-cells undergo
processes of birth at rates b0 and b, respectively, and loss at rates d0 and d,
respectively (via death or terminal differentiation), which may be affected
by endogenous or xenobiotic exposures, with b > d (positive net prolifera-
tion) being characteristic of P-cells (Moolgavkar 1983; Moolgavkar et al.
1988; Moolgavkar and Luebeck 1990). In view of the brief periods of expo-
sure and follow-up, it was assumed for simplicity that N is constant (as an
effective time-weighted average scaling factor), b0 ≈ d0 (steady-state tissue
maintenance) for N-cells, and the product v = N m1 was fit to each control
tumor incidence rate. Assuming that DBP acted as a pure mutagen, the
MVK model was evaluated with parameters mi = m0(1 + qi C(t)), (for 
i = 1,2), assuming m0 = 10
–6 (representing a single background mutation
rate), b = g, and d = d0, where qi denote “potency” coefficients for DBP-
induced mutations), and C(t) = DBP concentration in ppm at time t (mea-
sured in months), with C(t) = 0 if t ≤ 2 or t > 3. Assuming alternatively that
DBP is a purely non-mutagenic tumor promoter that acts only to increase
the net rate of proliferation of premalignant cells, the MVK model was
evaluated with parameters mi = m0 (for i = 1,2), and b = g(1 + q1 C(t))
exp(–q2 C(t)) + d, and d = d0, where q1 and q2 here denote potency and
potency-attenuation coefficients, respectively, for DBP-induced net prolif-
eration of P-cells, and q2 > 0 was assumed only for liver tumors to better
model the non-monotonic response pattern observed for that tumor end-
point. Fits using an MVK model parameterized to reflect a dual MOA,
involving DBP-induced elevations both in mutation rates and in net rates
of premalignant-cell population growth, were also explored (see Results).
To simplify DAH-model implementation, in view of the driving role of
transient production of all preneoplastic (PB and RM) cells in proportion
to the total duration of AH-generating stress that is predicted by the DAH
model (see Introduction), and the fact that tumor histology information
Models Fit to ED001 Tumor Data
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was not reported by Bailey et al. (2009) as noted above, tumors were all
assumed to be malignant. In the absence of time-to-tumor data, this
assumption did not clearly constrain modeling results to predict respons-
es that differ substantially from those that could be obtained by modeling
separate benign and malignant DAH pathways. The DAH model was
implemented by adapting the MVK (two-stage, doubly stochastic Poisson-
process) model to reflect a characteristic DAH-specific parameter struc-
ture. Specifically, the MVK-model parameters were adapted as follows: N
= 1, m1 = m0[1 + q1 C(t) exp(–d C(t))] {1 + 10
3 q2 Φ([ln(C(t)) –
ln(μ)]/ln(σg))} with d = 2 q1 (liver) or d = 0 (stomach), m2 = 10
–3, b = 1, d
= 3/4 or 1/2 (for liver or stomach, respectively), where qi denote hypo-
thetical linear (i = 1) and nonlinear (i = 2) potency coefficients for DBP-
induced regenerative AH, Φ = the standard normal cumulative probabil-
ity distribution function (cdf), and ln = natural logarithm. Increased
tumor risk due to DBP-induced AH was thus assumed to reflect a domi-
nant pathway requiring the interaction of a mutation event, assumed to
occur at a rate proportional to q1 C(t), and the size of the regenerative
AH-cell population in each target tissue, assumed to be proportional to a
cumulative lognormal function of concentration C(t) with a median
response at C(t) = μ and a geometric standard deviation of σg. The DAH
model was first fit to both ED001 data sets conditional on q1 = 1/200 (cho-
sen arbitrarily); additional fits to stomach-tumor data were obtained
using three additional values of q1 in the range 0 ≤ q1 ≤ 1/10 to demon-
strate that DAH-model goodness of fit is effectively independent of q1
within this range (see Results).
Calculations and Statistical Analysis
The significance of tumor-incidence elevation observed in each expo-
sure group compared to controls was assessed by Fisher exact test. The
MVK and DAH models described were evaluated numerically by the
method of Crump et al. (2005) to evaluate predicted cumulative proba-
bility R(C) of observing each tumor type at time t = 12 months after expo-
sure to DBP concentration C during period 2 ≤ t < 3 (see Appendix). All
four models were fit by inverse-variance weighted Levenberg-Marquardt
minimization of a chi-square objective function comparing the fitted to
observed tumor incidence rates, assuming binomial sampling errors
(except as noted above for liver tumor counts in the 28.4-ppm concen-
tration group), and associated covariances were used to calculate asymp-
totic chi-square goodness-of-fit statistics (Press et al. 1986). Additionally,
low-dose data subsets for each tumor type were each tested for approxi-
mate linearity of dose-response using a corresponding chi-square good-
ness-of-fit statistic from inverse-variance-weighted linear regression.
Biologically based model predictions of increased tumor-specific risk
above background were compared graphically. For this comparison,
K. T. Bogen
392
7
Bogen: Models Fit to ED001 Tumor Data
Published by ScholarWorks@UMass Amherst, 2014
increased risk A(C) to DBP-exposed trout above background risk R(0) for
each tumor type was extrapolated at low doses using each well-fitting bio-
logically based model, assuming that R(0) arises independent of DBP
exposure: i.e., assuming that A(C) = [R(C)–R(0)]/[1–R(0)]. For the
DAH model applied to stomach tumors, an exact expression for the lim-
iting value of A(C) as C tends to zero was obtained by symbolically evalu-
ating the (quite complicated) exact analytic expression obtained for the
corresponding MVK model evaluated at time t = 12, after a total of k = 3
periods each involving constant model-parameter values, using the piece-
wise-recursive formula derived by Moolgavkar and Luebeck (1990) for
risk R(C) conditional on k.
All numerical calculations and symbolic (including algebraic, deriva-
tive, and limit) calculations were performed using Mathematica® 9.0 soft-
ware (Wolfram Research 2013). P-values <10–10 were indicated as being
~0.
RESULTS
Compared to control-group incidence rates by Fisher exact tests, liver
tumors were not elevated significantly at the lowest two DBP concentrations
used in the ED001 study (p ≥ 0.39), but were clearly elevated (p = 10
–9) in
the third-highest (3.57-ppb) DBP-exposure group that had a liver-tumor
incidence rate of 0.82%, as well as in all higher dose groups (p = ~0).
Similar pairwise comparisons showed that stomach tumors were not ele-
vated significantly at the lowest three DBP concentrations used (p ≥ 0.39),
were marginally elevated (p = 0.061) in the third-highest exposure group,
were significantly elevated (p = 0.020) in the forth-highest (10.1-ppb)
DBP-exposure group that had a stomach-tumor incidence rate of 0.51%,
as well as in all higher dose groups (p = ~0).
Table 1 lists parameter estimates from fits to data on liver and stom-
ach tumors in ED001-study trout obtained using the biologically based,
mechanistic MVK and DAH models, together with goodness-of-fit statis-
tics. Neither the purely genotoxic MVK model nor the MS2 model are
plausibly consistent with either set of tumor data (p = ~0), whereas good
(p = ~0.5) and nearly identical fits to data on each tumor type were
obtained using the purely nongenotoxic MVK model and the DAH
model. The purely nongenotoxic MVK and DAH model fits are com-
pared in Figure 2. Fits of the MVK model parameterized initially to reflect
a dual MOA (i.e., both genotoxic and nongenotoxic pathways to
increased tumor risk) converged on the pure nongenotoxic MVK fits list-
ed in Table 1, so the latter fits represent the best MVK-model fits obtained
to ED001 data on each tumor endpoint.
Figure 3 plots tumor- and model-specific increased risks predicted by
the nongenotoxic (pure-promoter) MVK model (blue curves), and by the
DAH model (black curves). In this figure, the fit to liver-tumor data
Models Fit to ED001 Tumor Data
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shown (blue dashed curve) assumed a value of 0.005 for the DAH-model
parameter q1, which specifies the potency with which DBP is assumed to
increase the critical DAH-mutation rate. To obtain the four DAH-model
fits to stomach-tumor data shown (as black dotted curves) in Figure 3,
Models Fit to ED001 Tumor Data
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FIGURE 2. Nongenotoxic or “pure promoter” MVK model (blue curves) and DAH model (balck
curves) fit to ED001 “mega-trout” study data (open points) on the incidence of liver tumors (solid
curves) and stomach tumors (dashed curves) in Shasta strain trout fry fed different concentrations
of DBP for four weeks, then followed on control diet for nine months before sacrifice. Error bars
denote ±1 SE. 
FIGURE 3. Each of the risk models plotted in Figure 2 in relation to the tumor data is re-plotted here
with the Y-axis re-expressed as increased tumor risk over each corresponding background risk esti-
mated to occur in the absence of DBP exposure. The DAH-model fits each involve a parameter q1
that defines assumed mutagenic potency. A q1 value of 0.005 was assumed for the DAH-model fit to
liver-tumor data (blue dashed curve). Four different values of q1 (including 0.005, as indicated) were
used to obtain four corresponding fits to stomach-tumor data (dotted black curves). 
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four different corresponding values of q1 were assumed (including the
value q1 = 0.005) as indicated in the figure. At very low DBP concentra-
tions (< ~1 ppm) administered for four weeks, the fits to liver- and to
stomach-tumor data that were made using the purely nongenotoxic MVK
model are ~550-fold and ~120-fold greater, respectively, than those made
using the DAH model conditional on q1 = 0.005. Figure 3 illustrates how
the magnitude of this MVK-to-DAH ratio of predicted, model-specific
increased risk is directly and linearly proportional to the assumed value
of the DAH-model parameter q1.
As values of maximum DBP concentration C = Max[C(t)] approach 0,
the terms involving exp and Φ in the DAH-model expression given in
Methods clearly reduce to 1 and 0, respectively. Conditional on this sim-
plification, analysis (as described in Methods) of the DAH model yielded
the following corresponding exact expression for increased risk A(C) as
a function of C in the limit as C→0, as a function of model parameters m0
and q1:
A(C) = {(r1/2000) – ln[(r2 + r1 X)/(r2 + r1 X
9/10)]}m0 q1 C 
= ~0.16011 m0 q1 C, (1)
where r1 = R–c, r2 = R+c, R = , c = 499, and X = exp(R/100) (see
Appendix). As illustrated in Table 1 for DAH fits to the stomach tumor
data, when DAH-model parameters are re-optimized using different val-
ues of q1 in the range 0 ≤ q1 ≤ 1/10, all the resulting fits are good and vir-
tually identical within the range of the data. Each such fit involves a vir-
tually identical value of m0, which essentially fits the background tumor
rate. Optimizing the two lognormal parameters contained in the DAH
model thus generates the good fit achieved to all the non-background
data for each tumor type. Numerical evaluations of the DAH model that
was fit to stomach-tumor data show that for all C ≤ 0.1 ppm, Equation 1 is
accurate to within ~2.5% for all q1 ≤ 1/10 and to within ~0.5% for all q1
≤ 1/40. Because models found to fit well to data on both tumor endpoints
(Table 1) are structurally similar, analogous results are expected con-
cerning how well Equation 1 approximates DAH-model fits to data on
liver tumors, conditional on similar ranges for the values of q1 and C.
Consequently, the DAH model applied essentially combines a lognormal
dose-response model that dominates at higher doses, together with a
“hockey-stick”-type model that dominates at much lower doses, over
which the limiting linear “hockey-stick” dose-response slope is deter-
mined entirely by the mutagenic-potency parameter q1 (Figure 3).
Stepwise chi-square goodness-of-fit tests for consistency with dose-
response linearity, each performed on a tumor-specific dose-response
data subset consisting of the k lowest-concentration data points, showed
that the liver-tumor data subset, including the 3.57-ppm exposure group
253001
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exhibiting a 0.82% rate of liver-tumor incidence, was found to be only
marginally consistent with linearity (k = 4, p = 0.054); all larger subsets of
the concentration-ordered liver-tumor data (i.e., those including the
10.1-ppm exposure group exhibiting a 5.5% rate of liver-tumor inci-
dence) were clearly inconsistent with linearity (k ≥ 5, p < 10–8). Dose-
response linearity was thus determined to be plausible only for rates less
than 2% of that observed for liver tumors in the highest DBP-concentra-
tion group studied.
Dose-response linearity for DBP-induced stomach tumors was likewise
determined to be rejected only when the third-highest dose group (4.6%
of which developed stomach tumors) was included (k = 6, p = 0.00015).
Dose-response linearity was thus determined to be plausible only for rates
less than ~6% of that observed for stomach tumors in the highest DBP-
concentration group studied.
DISCUSSION AND CONCLUSIONS
Results from the present study show that the two biologically based,
mechanistic models of tumorigenesis (MVK and DAH) examined each
provide good fits to liver- and stomach-tumor incidence data from the
ED001 study. Surprisingly and counter-intuitively, however, the good MVK
model fits obtained that are listed in Table 1 all assume a purely nongeno-
toxic MOA, in each case with zero predicted contribution from exposure-
induced mutations by one of the most potently mutagenic carcinogens
known. The nongenotoxic MVK model applied expresses increased net
proliferation of premalignant cells as a linear function of DBP concen-
tration. Nevertheless, predictions made by this model were found to be
consistent with a lognormal pattern of observed responses in relation to
DBP concentration that is exhibited by the DAH model that was fit to the
same tumor data.
The observation that nongenotoxic MVK-model fits listed in Table 1
are each statistically consistent with the data to which these models were
fit, while corresponding genotoxic MVK-model fits are not plausibly con-
sistent with those data, does not prove that DBP-induced mutations
played no role in elevating tumor incidence in the ED001 study. As noted
in Results, a low-dose subset of each tumor-specific data set is clearly sta-
tistically consistent with an LNT dose-response. Even if none of the data
were determined to be statistically consistent with low-dose linearity, from
a statistical standpoint, it is a well-recognized practical impossibility to dis-
prove that an LNT dose-response does not actually occur at sufficiently
low doses for any endpoint, particularly if it occurs spontaneously at a
non-negligible rate, even using tens of thousands of experimental ani-
mals as done in the ED001 study. However, as also noted in Results, each
subset of ED001-study data found to be consistent statistically with low-dose
linearity was also found to be rather limited, representing very small frac-
Models Fit to ED001 Tumor Data
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tions—less than about 2% and 6%—of the maximum rates of incidence
observed for liver and stomach tumors, respectively. These are rather
small upper statistical bounds on the plausible contribution of low-dose
linearity to tumor rates increased by exposure to DBP, one of the most
potently mutagenic carcinogens known.
Forward mutations are potently induced by DBP, and are readily
detected in animal cells in vitro and in vivo as approximately linear func-
tions of exposure, even at concentrations that are at most marginally cyto-
toxic (see Introduction). Therefore, if the somatic-mutation/MVK model
of cancer is valid, MVK-model fits obtained to ED001-study tumor data
should have involved estimated increases above background mutation
rates, and corresponding low-dose dose-response linearity over response
ranges that extend beyond merely marginal elevations above background
tumor rates. This expectation is clearly inconsistent with the modeling
results obtained for liver tumors discussed, and possibly also with those
for stomach tumors, even after addressing plausible bounds on statistical
uncertainty that pertains to the lowest portions of each observed tumor
dose-response pattern. Thus, while MVK-modeling results were obtained
that are statistically consistent with ED001-study tumor data, the results do
not appear to be biologically plausible because they imply that DBP-
induced mutations played implausibly small or even no role in tumori-
genic effects that were potently elicited by DBP exposure.
Like the MVK model, the mechanistic DAH model also assumes that
mutation plays a critical, rate-limiting role in tumorigenesis. However, the
DAH model places no lower bound on the assumed positive magnitude
of this role. If the single critical mutation posited by the DAH model for
each tumor type is typically extremely rare, then this model predicts that
elevated tumor incidence after sustained chemical exposure can arise pri-
marily (or solely) by an associated increase in the number of cells recruit-
ed into AH-cell populations that, according to this model, most typically
are the source of exposure-induced tumors. The DAH model thus pro-
vides one example of a mechanistic, biologically based model of tumori-
genesis that happens to provide good fits to ED001 tumor data, based on
modeling assumptions that are consistent with data concerning different
toxic cellular effects of DBP. However, the fact that good DAH-model fits
were obtained, of course, may instead simply coincidentally reflect the
approximate lognormal pattern that happens to be exhibited by both
tumor types that were elevated by DBP in the ED001 study.
At very low DBP concentrations (less than about 1 ppm) administered
for four weeks, the fits to liver- and to stomach-tumor data obtained using
the purely nongenotoxic MVK model were determined to be ~550-fold
and ~120-fold greater, respectively, than those obtained using the biolog-
ically based, mechanistic DAH model conditional on a value of 0.005 for
the DAH-model parameter q1 (Figure 3). The magnitudes of these rela-
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tive differences in predicted increased risk are effectively arbitrary,
because Equation 1 (see Results) implies that these relative differences in
predicted increased risk are linearly proportional to the value of the q1
parameter used to implement the DAH model, over a fairly large q1-range
bounded by zero. As noted in Results, the DAH model thus exhibits a
dose-response pattern that combines an “arbitrary-slope hockey-stick” at
low doses, with a lognormal S-shaped response at higher doses. Thus
when DAH-model fits to each tumor set are conditioned on different val-
ues of q1, the goodness of fit remains virtually unaffected, but the “slope”
of the low-dose hockey-stick part of the fit is re-scaled in proportion to q1.
When the Y-axis is log-transformed as in Figure 3, this re-scaling of slope
appears as a vertical shift of the low-dose portions of the fitted (dotted
black) curves (i.e., the portions at which DBP concentration is less than
~1 ppm), which each have unit slope on a log scale.
The ED001 “mega-trout” bioassay offers the greatest statistical power
currently available to resolve different low-dose dose-response relation-
ships for tumors induced by a genotoxic chemical carcinogen. Substantial
(>10-fold) improvement in statistical power in this regard is unlikely to
arise for years or perhaps decades. Consequently, a direct experimental
test between low-dose dose-response predictions made, for example, by
the DAH vs. the MVK model using animal bioassay data, is not feasible
either currently or perhaps even within the next decade. At this point,
such a comparison can be made only by generating additional experi-
mental data and by improving theory concerning fundamental molecu-
lar mechanisms of tumorigenesis. Such developments thus continue to be
the long-recognized key to improved risk assessment for environmental
chemical carcinogens (Albert 1994).
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APPENDIX
All MVK and DAH models fit were implemented numerically as the
solution for predicted cumulative likelihood R(t) that a malignant cell
appears by time t = 12 months for a general MVK model expressed in
terms of the parameters v(t), m2, b(t), and d, which were defined in
Methods in fundamentally different ways for each model considered, as
indicated where applicable as functions of time t. Crump et al. (2005)
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showed that a general solution for R(t) = 1 – C(t, t), can be evaluated by
numerically solving the following linked system of ordinary differential
equations involving three auxiliary variables (A, B, and C) each a func-
tion of starting time s and ending time t, with 0 ≤ s ≤ t:
dA(s, t)/dt = b(t–s) A2(s, t) + d – [b(t–s) + d – m2]A(s, t) (A-1)
dB(s, t)/dt = 2b(t–s) A(s, t) B(s, t) + d
– [b(t–s) + d – m2]A(s, t) (A-2)
dC(s, t)/dt = v(t–s) C(s, t) [A(s, t) – 1], (A-3)
with initial conditions A(0, t) = C(0, t) =1 and B(0, t) = –m2. For piecewise-
constant parameters, R(t) can also be solved analytically (see below).
From the general analytic solution by Moolgavkar and Luebeck
(1990) defining R(t) for an MVK model with piecewise-constant parame-
ters during intervals 0 ≤ t < 2, 2 ≤ t < 3, and t ≥ 3, the exact value of R(t)
for the DAH model described in Methods with parameters v = ~m0(1 + q1
C) for very small maximum DBP concentration C, m2, b, and d is given by
R(t) = 1 – exp[–(m0/b) {A + F ln(S2/S3) 
+ ln[B S3/(2 r S2)]}], (A-4)
where A = (h–r)F/2, h = b–d–m2, r = [(b+d+m2) – 4 b d]
1/2, F = 1 + q1 C, B
= (r+h) + (r–h)Xt, X = exp(r), Si = r + b – d – m2 + (r – b + d + m2)X
t–i, t =
12, i = 1,2, and ln denotes natural logarithm. Mathematica 9.0® symboli-
cally calculated the derivative of increased risk A(C), defined in Methods,
with respect to C in the limit as C→0 as
LimC→0[dA(C)/dC] = {[b – d – m2 – r 
+ 2 ln(S2/S3)]/(2 b)} m0 q1 , (A-5)
which, using definitions given above and multiplying by C, yields
Equation 1 (in Results) after substituting values of m0, m2, b, and d defined
in Methods for the DAH model.
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